NCT06346067 2026-02-27
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Erasca, Inc.
Phase 3 Active not recruiting
Clinical Trials
8 trialsNCT04940052 2025-12-02
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
Novartis
Phase 3 Active not recruiting
NCT02967692 2025-09-18
COMBI-i
Novartis
Phase 3 Terminated
NCT03551626 2025-04-29
COMBI-APlus
Novartis
Phase 3 Completed
NCT01682083 2023-08-30
COMBI-AD
Novartis
Phase 3 Completed
NCT01597908 2021-02-24
COMBI-v
Novartis
Phase 3 Completed
NCT01584648 2021-02-17
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Novartis
Phase 3 Completed
NCT01245062 2018-04-05
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
GlaxoSmithKline
Phase 3 Completed